N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Neuroblastoma
Interventions
DRUG

fenretinide

OTHER

high performance liquid chromatography

OTHER

pharmacological study

Trial Locations (13)

10032

Morgan Stanley Children's Hospital of New York-Presbyterian, New York

30322

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta

60637

University of Chicago Comer Children's Hospital, Chicago

76104

Cook Children's Medical Center - Fort Worth, Fort Worth

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

94304

Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

90027-0700

Childrens Hospital Los Angeles, Los Angeles

02115

Children's Hospital Boston, Boston

48109-0286

C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

77030-2399

Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Nant Operations Center

OTHER

NCT00646230 - N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma | Biotech Hunter | Biotech Hunter